Stocks · News reference
SciSparc shares are trading higher after the company announced its subsidiary, NeuroThera labs, continued advancement in participant enrollment for the clinical trial assessing the SCI-210 treatment for symptoms associated with autism spectrum disorder
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading